Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

   Completed · Open-angle Glaucoma

   NCT04647214 · AbbVie Inc. · 3 U.S. investigators

   $209,652research payments

2. A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

   Completed · Phase 3 · Childhood Absence Epilepsy

   NCT04666610 · UCB SA · 7 U.S. investigators

   $209,410research payments

3. Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

   Completed · Phase 2 · Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

   NCT05014815 · Beigene, Ltd. · 2 U.S. investigators

   $208,831research payments

4. A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

   Terminated · Phase 1 · Hepatic Impairment

   NCT04241835 · Epizyme, Inc. · 7 U.S. investigators

   $207,343research payments

5. A Study of [14C]-LOXO-783 in Healthy Adult Participants

   Completed · Phase 1 · Healthy

   NCT06102512 · Eli Lilly and Company · 1 U.S. investigator

   $206,433research payments

6. A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

   Active, not recruiting · Phase 1, Phase 2 · Phenylketonuria

   NCT05972629 · Genzyme Corporation · 5 U.S. investigators

   $206,065research payments

7. An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

   Completed · Phase 3 · Generalized Myasthenia Gravis

   NCT05514873 · UCB SA · 11 U.S. investigators

   $205,833research payments

8. A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

   Recruiting · Phase 3 · Autosomal Recessive Polycystic Kidney (ARPKD)

   NCT04782258 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 8 U.S. investigators

   $205,326research payments

9. Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

   Terminated · Phase 1 · Squamous Cell Carcinoma of Head and Neck

   NCT04465487 · Regeneron Pharmaceuticals, Inc. · 5 U.S. investigators

   $204,407research payments

10. CemiplimAb Survivorship Epidemiology

    Completed · Cutaneous Squamous Cell Carcinoma

    NCT03836105 · Regeneron Pharmaceuticals, Inc. · 33 U.S. investigators

    $204,258research payments

11. Flexible-Dose Trial in Early Parkinson's Disease (PD)

    Completed · Phase 3 · Parkinson Disease

    NCT04223193 · AbbVie Inc. · 14 U.S. investigators

    $203,287research payments

12. Pounce™ Thrombectomy System Retrospective Registry

    Recruiting · Peripheral Arterial Disease

    NCT05868161 · Surmodics, Inc. · 10 U.S. investigators

    $201,997research payments

13. Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

    Completed · Phase 4 · Moderate to Severe Opioid-use Disorder

    NCT04995029 · Indivior Inc. · 6 U.S. investigators

    $201,905research payments

14. A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

    Completed · Phase 2 · Plaque Psoriasis

    NCT06176768 · Eli Lilly and Company · 11 U.S. investigators

    $201,747research payments

15. A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

    Active, not recruiting · Hemophilia A

    NCT05911763 · Sanofi US Services Inc. · 27 U.S. investigators

    $201,594research payments

16. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

    Recruiting · Phase 3 · Crohn's Disease

    NCT05509777 · Eli Lilly and Company · 5 U.S. investigators

    $200,969research payments

17. Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

    Recruiting · Phase 2 · Non-cystic Fibrosis Bronchiectasis

    NCT07048262 · Csl Behring · 12 U.S. investigators

    $199,713research payments

18. A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

    Recruiting · Phase 2 · Multiple Sclerosis

    NCT06735248 · ModernaTX, Inc. · 11 U.S. investigators

    $196,609research payments

19. Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

    Active, not recruiting · Phase 3 · Psoriasis

    NCT04862286 · AbbVie Inc. · 14 U.S. investigators

    $196,147research payments

20. A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

    Recruiting · Phase 3 · Juvenile Psoriatic Arthritis

    NCT06100744 · AbbVie Inc. · 10 U.S. investigators

    $195,326research payments

21. AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study

    Completed · Gall Bladder Disease

    NCT06364865 · Teleflex LLC · 3 U.S. investigators

    $195,234research payments

22. Teplizumab in Pediatric Stage 2 Type 1 Diabetes

    Completed · Phase 4 · Diabetes Mellitus, Type 1

    NCT05757713 · Sanofi US Services Inc. · 3 U.S. investigators

    $193,880research payments

23. Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

    Active, not recruiting · Phase 2 · Classical Hodgkin Lymphoma

    NCT02940301 · AbbVie Inc. · 1 U.S. investigator

    $193,517research payments

24. A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

    Completed · Phase 2 · Acute Ischemic Stroke

    NCT04309474 · AbbVie Inc. · 11 U.S. investigators

    $192,130research payments

25. Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease

    Completed · Carotid Artery Diseases

    NCT05365490 · Boston Scientific Corporation · 41 U.S. investigators

    $190,538research payments

26. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

    Recruiting · Phase 3 · Clear Cell Renal Cell Carcinoma

    NCT06661720 · Aveo Pharmaceuticals, Inc. · 1 U.S. investigator

    $189,723research payments

27. A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

    Completed · Phase 2, Phase 3 · Alopecia Areata

    NCT03570749 · Eli Lilly and Company · 38 U.S. investigators

    $189,147research payments

28. A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

    Completed · Phase 3 · Thrombotic Thrombocytopenic Purpura (TTP)

    NCT03393975 · Takeda Pharmaceuticals U.S.A., Inc. · 3 U.S. investigators

    $187,851research payments

29. A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

    Completed · Phase 2 · Gastroesophageal Reflux Disease (GERD)

    NCT02616302 · Takeda Pharmaceuticals U.S.A., Inc. · 6 U.S. investigators

    $187,477research payments

30. A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants

    Completed · Phase 1 · Healthy

    NCT06627088 · Eli Lilly and Company · 1 U.S. investigator

    $186,151research payments

31. A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

    Recruiting · Phase 1 · Parkinson Disease

    NCT06809400 · Eli Lilly and Company · 1 U.S. investigator

    $185,015research payments

32. Tislelizumab in People With Colorectal Cancer

    Recruiting · Phase 2 · Colorectal Cancer

    NCT06529523 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $184,500research payments

33. A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

    Active, not recruiting · Phase 3 · Melanoma

    NCT05625399 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $184,060research payments

34. A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

    Recruiting · Phase 3 · Chronic Idiopathic Constipation (CIC)

    NCT07382167 · Ardelyx, Inc. · 13 U.S. investigators

    $183,250research payments

35. A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

    Recruiting · Phase 1 · Recurrent or Metastatic Solid Tumors

    NCT07015697 · Daiichi Sankyo Inc. · 4 U.S. investigators

    $182,345research payments

36. Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

    Active, not recruiting · Phase 1, Phase 2 · Blastic Plasmacytoid Dendritic Cell Neoplasm

    NCT03386513 · AbbVie Inc. · 6 U.S. investigators

    $181,832research payments

37. Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

    Recruiting · Waldenstrom Macroglobulinemia

    NCT05640102 · Beone Medicines USA, Inc. · 16 U.S. investigators

    $180,482research payments

38. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    Active, not recruiting · Phase 1, Phase 2 · Advanced Solid Tumor

    NCT04145622 · Daiichi Sankyo Inc. · 2 U.S. investigators

    $178,636research payments

39. A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

    Completed · Phase 3 · Hemophilia A

    NCT02615691 · Takeda Pharmaceuticals U.S.A., Inc. · 10 U.S. investigators

    $178,203research payments

40. BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

    Terminated · Phase 1 · Advanced Solid Tumor

    NCT05935098 · Beone Medicines USA, Inc. · 4 U.S. investigators

    $178,107research payments

41. Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

    Completed · Phase 1 · Opioid Use Disorder

    NCT05547542 · AbbVie Inc. · 1 U.S. investigator

    $177,517research payments

42. Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

    Terminated · Phase 1 · Osteogenesis Imperfecta

    NCT05231668 · Genzyme Corporation · 6 U.S. investigators

    $177,461research payments

43. A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

    Completed · Phase 2 · Hidradenitis Suppurativa

    NCT05849922 · Sanofi US Services Inc. · 6 U.S. investigators

    $177,097research payments

44. A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

    Terminated · Phase 3 · RSV Immunisation

    NCT06705140 · Sanofi Pasteur Inc. · 13 U.S. investigators

    $176,552research payments

45. Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

    Completed · Phase 3 · Thrombotic Thrombocytopenic Purpura

    NCT05468320 · Genzyme Corporation · 11 U.S. investigators

    $176,308research payments

46. A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

    Completed · Phase 1 · Healthy Volunteer

    NCT06278766 · AbbVie Inc. · 1 U.S. investigator

    $174,488research payments

47. An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

    Status unknown · Phase 4 · Primary Immune Deficiency

    NCT05070455 · Adma Biomanufacturing LLC · 0 U.S. investigators

    $174,235research payments

48. An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

    Active, not recruiting · Juvenile Idiopathic Arthritis

    NCT01357668 · E.r. Squibb & Sons, L.l.c. · 16 U.S. investigators

    $173,478research payments

49. A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

    Active, not recruiting · Phase 3 · Hypertension

    NCT06948422 · Eli Lilly Export S.a. Puerto Rico Branch · 1 U.S. investigator

    $172,481research payments

50. An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

    Terminated · Phase 2 · Seizures

    NCT04686786 · AbbVie Inc. · 19 U.S. investigators

    $172,248research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.